The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Xilio Therapeutics Inc shares valued at $1,830,377 were purchased by GILEAD SCIENCES, INC. on Dec 18 ’24. At $1.04 per share, GILEAD SCIENCES, INC. acquired 1,759,978 shares. The insider’s holdings grew to 9,105,451 shares worth approximately $8.56 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, GILEAD SCIENCES, INC. purchased 485,250 shares, netting a total of over 368,790 in proceeds. Following the buying of shares at $0.76 each, the insider now holds 7,345,473 shares.
Before that, Atlas Venture Fund XI, L.P. had sold 733 shares from its account. In a trade valued at $469, the 10% Owner traded Xilio Therapeutics Inc shares for $0.64 each. Upon closing the transaction, the insider’s holdings decreased to 733 shares, worth approximately $1.9 million.
As published in their initiating research note from Chardan Capital Markets on December 21, 2022, Xilio Therapeutics Inc [XLO] has been a Buy and the price target has been revised to $7. Analysts at H.C. Wainwright started covering the stock with ‘”a Buy”‘ outlook in a report released in early January. As of November 16, 2021, Raymond James has initiated its “an Outperform” rating for XLO. Earlier on November 16, 2021, Morgan Stanley initiated its rating. Their recommendation was “an Overweight” for XLO stock.
Analyzing XLO Stock Performance
During the last five days, there has been a drop of approximately -8.93%. Over the course of the year, Xilio Therapeutics Inc shares have jumped approximately 70.55%. Shares of the company reached a 52-week high of $1.9300 on 03/28/24 and a 52-week low of $0.5001 on 02/14/24. A 50-day SMA is recorded $1.0021, while a 200-day SMA reached $0.9683. Nevertheless, trading volume fell to 3.72 million shares from 0.17 million shares the previous day.
Support And Resistance Levels for Xilio Therapeutics Inc (XLO)
According to the 24-hour chart, there is a support level at 0.8727, which, if violated, would cause prices to drop to 0.8073. In the upper region, resistance lies at 0.9767. The next price resistance is at 1.0153. RSI (Relative Strength Index) is 45.04 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.0969, which suggests the price will decrease in the coming days. Percent R is at 60.67%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
